CIK 0001743881 · Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,563,798
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,563,798. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-08 | HOMCY CHARLES J Director | Sale 10b5-1 | −191,662 | $45.87 | $8.8M | 1,025,012 |
| 2025-08-08 | HOMCY CHARLES J Director | Sale 10b5-1 | −58,338 | $46.64 | $2.7M | 966,674 |
| 2025-08-08 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −11,795 | $45.88 | $541K | 4,726,652 |
| 2025-08-08 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −8,205 | $46.71 | $383K | 4,718,447 |
| 2025-08-08 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −11,795 | $45.88 | $541K | 923,891 |
| 2025-08-08 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −8,205 | $46.71 | $383K | 915,686 |
| 2025-08-07 | Apuli Maricel Chief Accounting Officer | Sale | −1,000 | $45.44 | $45K | 141,859 |
| 2025-08-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −6,784 | $45.09 | $306K | 4,751,663 |
| 2025-08-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −13,216 | $45.64 | $603K | 4,738,447 |
| 2025-08-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −6,784 | $45.09 | $306K | 948,902 |
| 2025-08-07 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −13,216 | $45.64 | $603K | 935,686 |
| 2025-08-05 | Ellis Andrea Director | Option exercise 10b5-1 | +17,167 | $16.75 | $288K | 35,756 |
| 2025-08-05 | Ellis Andrea Director | Sale 10b5-1 | −17,167 | $49.00 | $841K | 18,589 |
| 2025-08-05 | Ellis Andrea Director | Option exercise · Stock Option (right to buy) 10b5-1 | −17,167 | 34,334 | ||
| 2025-07-02 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −20,000 | $42.73 | $855K | 4,758,447 |
| 2025-07-02 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −20,000 | $42.73 | $855K | 955,686 |
| 2025-07-01 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −18,300 | $42.50 | $778K | 4,780,147 |
| 2025-07-01 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −1,700 | $42.88 | $73K | 4,778,447 |
| 2025-07-01 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −18,400 | $42.51 | $782K | 977,286 |
| 2025-07-01 | Kumar Neil Chief Executive Officer | Sale 10b5-1 | −1,600 | $42.89 | $69K | 975,686 |
Page 16 of 19 · 379 trades